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Available online 11 January 2013Abstract To develop cell therapies for damaged nervous tissue with human neural stem/progenitor cells (hNPCs), the risk of an
immune response and graft rejection must be considered. There are conflicting results and lack of knowledge concerning the
immunocompetence of hNPCs of different origin. Here, we studied the immunogenicity and immunomodulatory potentials of hNPCs
cultured under equivalent conditions after derivation from human embryonic stem cells (hESC-NPCs) or human fetal spinal cord tissue
(hfNPCs). The expression patterns of human leukocyte antigen, co-stimulatory and adhesionmolecules in hESC-NPCs and hfNPCswere
relatively similar and mostly not affected by inflammatory cytokines. Unstimulated hfNPCs secreted more transforming growth
factor-β1 (TGF-β1) andβ2 but similar level of interleukin (IL)-10 compared to hESC-NPCs. In contrast to hfNPCs, hESC-NPCs displayed
4–6 fold increases in TGF-β1, TGF-β2 and IL-10 under inflammatory conditions. Both hNPCs reduced the alloreaction between
allogeneic peripheral blood mononuclear cells (PBMCs) and up-regulated CD4+CD25+forkhead box P3 (FOXP3)+ T cells. However,
hESC-NPCs but not hfNPCs dose-dependently triggered PBMC proliferation, which at least partly may be due to TGF-β signaling. To
conclude, hESC-NPCs and hfNPCs displayed similarities but also significant differences in their immunocompetence and interaction
with allogeneic PBMCs, differences may be crucial for the outcome of cell therapy.
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Neurodegenerative disorders and trauma of the central
nervous system (CNS) result in loss of neural cells and
include inflammatory and immune processes. Efforts have
been made at finding effective treatments to rescue neural
326 J. Liu et al.cells and counteract secondary degeneration and inflamma-
tion. Pharmacological therapy may slow down degenerative
processes but are still limited when it comes to restoration
of CNS functions. Human neural stem/progenitor cells
(hNPCs) can be derived from pluripotent embryonic stem
cells (hESCs), fetal CNS or induced pluripotent stem cells
(iPSCs) and have shown potential to restore functions.
Improvements of motor function have been demonstrated
in numerous animal models of Parkinson's disease (Morizane
et al., 2008) and spinal cord injury (SCI) (Tetzlaff et al.,
2011; Fujimoto et al., 2012). A rejection of donor neural
cells is however an inevitable concern, which must be
addressed for any such therapy.
The presence of human leukocyte antigen (HLA) class I
and II molecules (Odeberg et al., 2005; Ubiali et al., 2007;
Johansson et al., 2008; Laguna Goya et al., 2011) in
conjunction with co-stimulatory molecules CD40, CD80 and
CD86 (Odeberg et al., 2005) on hNPCs implies a risk for
recognition and rejection by non-compatible alloreactive
immune cells after transplantation. Varying results have
been reported in studies analyzing allogeneic T-cell prolif-
eration stimulated by hNPCs and their derivates from
different origins in in vitro assay. We previously reported
that hNPCs derived from first trimester nervous system
(hfNPCs) did not trigger an allogeneic lymphocyte response
(Odeberg et al., 2005). Similar findings on oligodendrocytes
derived from hESCs were reported by Okamura et al. (2007).
In contrast, Preynat-Seauve et al. (2009) found that
hESC-derived NPCs (hESC-NPCs) elicited a significant T cell
proliferation. Today, we also experimentally have the option
to derive human neural cells from iPSCs (Takahashi and
Yamanaka, 2006; Karumbayaram et al., 2009) or by direct
induction of differentiated cells to neural cells (Vierbuchen
et al., 2010), which may offer autologous neural cell therapy
with reduced ethical concerns and less risk of rejection.
However, even transplantation of syngeneic iPSCs can cause
an immune response (Zhao et al., 2011). Irrespective of
their origin, in vitro modified and expanded donor cells
may present changes in cellular characteristic and protein
expression, putting them at risk of being rejected. The aim
is to reduce the rejection risk with preserved therapeutic
potential.
Clinical trials with allogeneic neural cells most often
involve immunosuppressive treatments (Piccini et al., 2005;
Krystkowiak et al., 2007; Sandner et al., 2012), although it is
still not fully understood how immunogenic these cells are,
whether immunosuppression is a prerequisite and the
optimal drug, dose and duration.
The interaction between neural and immune cells is
complex. In contrast to triggering the immune system,
transplanted NPCs may interact with immune cells to
counteract a deleterious inflammatory environment in
rodent autoimmune disease models (Einstein et al., 2007;
Cusimano et al., 2012). It is not fully understood how these
neural cells exert their immunomodulatory effects and
whether the allogeneic human situation is similar.
In this study, we utilized human allogeneic in vitro model
system to evaluate the immunocompetence and immunomod-
ulatory potential of two promising donor neural cell
populations: hESC-NPCs and hfNPCs. The donor cells were
expanded, characterized and co-cultured with human periph-
eral blood mononuclear cells (PBMCs) under equivalentconditions, with and without inflammatory cytokines present,
to analyze host–donor interactions.
Materials and methods
Human embryonic stem cell culture
The hESC lines HS181, HS360 and HS401 were derived and
established in the Fertility Unit of Karolinska University Hospital
Huddinge, Sweden. hESCs were derived from the inner cell
mass of 5/6-day-old pre-implantation blastocyst-stage embryos
obtained after in vitro fertilization. The embryos used in this
study had been disqualified from infertility treatment and was
donated for hESC derivation after informed consent from the
couple. The Regional Ethics Committee, Stockholm, Sweden
has given approval for the derivation, expansion, and differen-
tiation of hESC lines (Ethics approval #454/02, Karolinska
Institutet). These cell lines were initially derived and cultured
using postnatal human foreskin fibroblasts (CRL-2429, ATCC) as
feeder cells and serum replacement (SR, Life Technologies, CA,
USA) medium as previously described (Inzunza et al., 2005).
hESC colonies were passaged by mechanical splitting at 5- to
7-day intervals and replated onγ-irradiated (35 Gy) fibroblasts.
The cell culture medium was changed once per day.
Later, suspension cultures were developed for hESCs to
reduce the risk of feeder cell contamination, by applying the
protocol developed by Steiner et al. (2010). Briefly, hESC
colonies were mechanically split and transferred to Neurobasal
medium containing 14% knockout-SR, 2 mM GlutaMax, 50 U/ml
penicillin/streptomycin, and 1% non-essential amino acids
(all from Life Technologies). The medium was supplemented
with 20 ng/ml human basic fibroblast growth factor (bFGF,
R&D, Minneapolis, MN, USA), 25 ng/ml activin A, brain-derived
neurotrophic factor (BDNF), neurotrophin (NT)-3 and NT-4,
10 ng/ml each (all from Peprotech, NJ, USA), 1 μg/ml
fibronectin (BD Biosciences, San Diego, CA, USA), 0.5 μg/ml
laminin, 0.001% gelatin (both from Sigma, St. Louis, MO, USA)
and 1× Nutridoma-CS (Roche, Bromma, Sweden). After
6–7 days, the colonies formed spheres and the spheres were
thereafter mechanically split every 7–10 days. The medium
was changed every other day. hESC spheres between passage 4
and 10 were used for neural induction, immunocytochemistry
and flow cytometry.
Neural induction of hESCs
The neural induction was performed with hESC spheres
according to the protocol by Chambers et al. (2009). Briefly,
the initial differentiation medium consisted of hESC-medium
with 10 μM TGF-β inhibitor SB431542 (Tocris, Bristol, UK)
and 500 ng/ml Noggin (R&D). Upon day 5 of differentiation,
increasing amounts of N2 medium (25%, 50% and 75%) was
added to the hESC-medium every two days while maintaining
10 μM SB431542 and 500 ng/ml Noggin. After 8 days of
neural induction, the spheres were cultured in neural stem/
progenitor cell (NS) medium (DMEM/F12, 0.6% glucose, 5 mM
Hepes, 2 μg/ml Heparin, 1% N2 supplement, all from Life
Technologies) supplemented with 20 ng/ml human epider-
mal growth factor (EGF) and 20 ng/ml bFGF (both from R&D)
and mechanically passaged once per week up to 20 weeks
after neural induction. All cultures were maintained in a
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was changed every other day. hESC-NPCs between passage
12 and 16 were used for the following experiments.
Human fetal neural stem/progenitor cells
Cultures of hfNPCs derived from human first trimester CNS
tissue (5–7.5 weeks of gestation). The procedure was approved
by the Regional Ethics Committee, Stockholm, Sweden (# 2008/
158-33/3, 2011/1101-32). Briefly, nervous system tissue was
retrieved from clinical first trimester routine abortions after
informed consent by the woman undergoing termination
of pregnancy. Identified spinal cord tissue was homogenized
with a glass-Teflon homogenizer and cultured at 100,000–
200,000 cells/ml in NS medium supplemented with 20 ng/ml
EGF, 20 ng/ml bFGF and 10 ng/ml ciliary neurotrophic factor
(CNTF) (all from R&D) as previously described (Akesson et al.,
2009). The cultures of free-floating neurospheres were pas-
saged every 7–14 days by enzymatical dissociation using TrypLE
Express (Life Technologies) and gentle trituration with fresh
medium added twice a week. All cultures were maintained in a
humidified atmosphere at 37 °C and 5% CO2. hfNPCs between
passage 5 and 10 were used in the following experiments.
Antibodies
All antibodies used in this study are listed in Supplementary
Tables 1 and 2.
Immunocytochemistry
The procedure was performed as previously described (Akesson
et al., 2009). Ten to fifteen intact neurospheres of hESC-NPCs
and hfNPCs were collected, fixed in 4% paraformaldehyde for
15 min at room temperature, treated with 30% sucrose
over night at 4 °C, mounted in Tissue-Tek mounting medium
(Sakura Finetek, Zoeterwoude, Netherlands) and frozen on dry
ice. The neurospheres were sectioned at a thickness of 5 μm,
pre-incubated with 10% normal goat or donkey serum for
30 min, incubatedwith primary antibody overnight at 4 °C, and
rinsed in phosphate-buffered saline (PBS) 3× 10 min. The
secondary antibody was added for 1 h at room temperature,
followed by a rinse in PBS 3 times. The cell nuclei were stained
with Hoechst 33342 (1:400, Life technologies) prior tomounting
with the coverslips in PVA-DABCO (9.6% polyvinyl alcohol, 24%
glycerol, and 2.5% 1,4-diazabicyclo (2.2.2) octane in 67 mM
Tris–HCl, pH 8.0). The images were examined in a fluorescence
microscope (Axiophot, Zeiss) and documented using a CCD
camera (ORCA-ER, Hamamatsu) together with the Openlab
software 3.1.7 for Macintosh (Improvision).
Flow cytometry
To stain surfacemarkers, cells were stainedwith the respective
antibodies at 4 °C for 30 min, washed, resuspended in PBS, and
fixed in Cytofix fixation buffer (BD Biosciences). FITC-, PE-,
PE-Cy5-, PE-Cy7-, PerCP-Cy5.5-, APC- and Alexa Fluor
647-conjugated isotype antibodies were used as controls. For
intracellular staining, the cells were fixed and permeabilized
by using a Cytofix/Cytoperm Fixation/Permeabilization Kit(BD Biosciences) following the manufacturer's instructions.
Thereafter, the cells were incubatedwith respective antibodies
at 4 °C for 30 min, washed and resuspended in PBS. hESCs were
used as control for some of the markers.
The expression of the various pluripotent, proliferation and
neural proteins by hNPCs are presented as percentage positive
cells: ≤25%=low, 26–75%=moderate, and 76–100%=high.
To analyze the expression levels of the Treg-markers CD4,
CD25 and forkhead box P3 (FOXP3), PBMCs were initially
labeled with antisera towards CD4 and CD25, fixed and
permeabilized with human FOXP3 buffer set (BD Biosciences)
and labeled with FOXP3 according to the manufacturer's
instructions.
Flow cytometry data were collected using a FACScalibur
(Becton and Dickinson) and data analysis on percentage of
positive cells and mean fluorescence intensity (MFI) was
performed with the software FlowJo (Tree Star, Inc.).
Stimulation with IFN-γ and/or TNF-α
hNPCs were stimulated in vitro with 200 U/ml interferon-
gamma (IFN-γ, R&D), 10 ng/ml tumor necrosis factor-alpha
(TNF-α, R&D) or a mixture of IFN-γ and TNF-α (200 U/ml and
10 ng/ml respectively) for 3 days. To compare hESC-NPCs and
hfNPCs under equivalent culture conditions, CNTFwas removed
from the culture medium of hfNPCs three days prior to analysis.
Neurospheres were dissociated into single-cell suspension for
flow cytometry analysis or for co-culture with PBMCs. The
medium was collected, centrifuged and the supernatant stored
at −80 °C for enzyme-linked immunosorbent assay (ELISA) as
described below.
Preparation of human PBMCs and purified T cells
Adult PBMCs were prepared by centrifuging peripheral
blood on a Ficoll gradient (Lymphoprep, Nycomed Pharma,
Oslo, Norway) at 500 g without brakes for 20 min at room
temperature. CD4 and CD8 T cells were sorted and purified
using anti-human CD3, CD4 and CD8 antibodies by FACSAria™
III (Becton and Dickinson).
Mixed lymphocyte cultures (MLCs)
This method has been described previously in detail (Ringden
and Berg, 1977; Gotherstrom et al., 2004). Briefly, 100,000
responder PBMCs (rPBMCs) or T cells from one donor were
co-cultured with 100,000 irradiated (20 Gy) stimulator
PBMCs (sPBMCs) or T cells from one or five donors. Triplicate
samples were cultured in 0.2 ml RPMI 1640 medium
supplemented with 100 U/ml penicillin, 100 mg/ml strepto-
mycin, 2 mM L-glutamine and 5% pooled normal human male
AB serum (RPMI medium, all from Life Technologies) per well in
96-well plates. The cell death, differentiation and expression
of HLA and co-stimulatory molecules by hNPCs after 6 days in
RPMI medium were analyzed by flow cytometry.
To study the effect of hNPCs on PBMC or T cell proliferation,
10,000 or 100,000 irradiated hESC-NPCs or hfNPCs (hNPCs:
rPBMC/T cells=1:10 or 1:1 ratio) were co-cultured. In some
experiments, hNPCs were exposed to IFN-γ and/or TNF-α for
three days prior to the co-culture, as described above. The
co-cultures were incubated at 37 °C and 5% CO2 for 6 days. On
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harvested after 24 h. [3H]thymidine incorporation was evalu-
ated using a semiautomatic harvesting machine (Harvester 96,
Tomec). Proliferation by PBMCs or T cells is presented as counts
per minute based on [3H]thymidine DNA incorporation. [3H]
thymidine incorporation in PBMCs or T cells co-cultured with
equal amount of irradiated autologous sPBMCs or T cells served
as negative controls, and the thymidine incorporation in PBMCs
co-cultured with equal amount of irradiated allogeneic pool of
sPBMCs from five incompatible donors served as positive
controls. Values below three times the background are
considered as negative.
The effect of neutralizing mAb to TGF-β1 (clone 9016,
R&D) was studied in MLC experiments. PBMCs from one
donor were co-cultured with hNPCs (hNPCs: rPBMC=1:10 or
1:1 ratio) for 6 days in the presence of the neutralizing mAb
at 10 ng/ml. Thymidine [3H] incorporation in responder
PBMCs was analyzed as described above.Immunomodulatory assay
To investigate how hNPCs affect PBMC sub-populations and
cytokine secretion in co-cultures, PBMCs included in the
co-culture system were labeled with carboxyfluorescein
diacetate succinimidyl ester (CFSE, Life Technologies)
according to manufacturer's instructions. Briefly, PBMCs
were resuspended at 1–10×106 cells/ml in warm PBS with
0.1% human serum albumin. CFSE was added to a final
concentration of 1 μM. Cells were incubated at 37 °C for
5 min, followed by the addition of ice-cold culture medium.
Cells were washed and resuspended in RPMI medium.
Non-irradiated hESC-NPCs or hfNPCs (5×105 cells/well in
6-well plates) were plated with an equal amount of
CFSE-labeled PBMCs in the same well. Equivalent cultures
were set up for other samples in Transwell system with two
chambers separated by a semi-permeable membrane with
the pore size of 0.4 μm (Millipore-Merck). hESC-NPCs or
hfNPCs were cultured in the upper chambers of the transwell
inserts while CFSE-labeled PBMCs were cultured in the lower
chambers. hESC-NPCs or hfNPCs and human PBMCs (1:1)
were co-cultured for 3 and 6 days. The cells were harvested
and the proportion of CD4+, CD8+, CD4+CD25+ and
CD4+CD25+FOXP3+ T cells (a subpopulation previously reported
by others (Dummer et al., 2012) to identify induced regulatory
T cells (Tregs)) were analyzed by flow cytometry. The
degree of T cell death in co-cultures was analyzed with
7-amino-actinomycin D (7-AAD) by flow cytometry. In addition,
the culture medium from the co-cultures was collected,
centrifuged and the supernatant stored at −80 °C for
quantitative analysis of secreted cytokine levels at day 6. In
some experiments, Brefeldin A (1:500, BD Biosciences) was
added to the culture medium during the last 6 h to block
cytokine secretion, followed by flow cytometric analysis.
To study effects of TGF-β1 and TGF-β2 on PBMC
proliferation, 150,000 PBMCs were cultured in the presence
of Phytohemagglutinin (PHA, 10 μg/ml, Sigma) in 96-well
plates for 4 days. Human recombinant TGF-β1 and TGF-β2
protein (R&D) were added to the culture at 0.01, 0.1, and
1 ng/ml and in the case of TGF-β1 also 10 ng/ml. The [3H]
thymidine incorporation in PBMCs was analyzed as described
above. The results were expressed as percentage of PBMCproliferation in the presence of PHA without hTGF-β1 or
hTGF-β2 (set as 100%).
Enzyme-linked immunosorbent assay (ELISA)
The ELISA reagents and components for transforming growth
factor-beta1 (TGF-β1), TGF-β2, interleukin (IL)-10, IL-6 and
TNF-α were purchased from R&D. The experimental proce-
dure was performed according to the manufacturer's in-
structions with Tris-buffered saline (TBS) as washing buffer.
The culture media from naïve hESC-NPCs and hfNPCs
neurosphere cultures with or without exposure to cytokines
for 3 days, or from co-culture experiments of hNPCs and
PBMCs in RPMI medium after 6 days were processed as
triplicate samples. The analysis of 96-well plates was
achieved in a TECAN Safire2 microplate reader (Männedorf,
Switzerland) at 540 nm.
Statistical analysis
Analysis of differences between groups was performed by
Kruskal–Wallis test with Dunn's post-hoc test or Mann–
Whitney test, using the Instat 3.0 software for Macintosh
computers (GraphPad Software Inc., La Jolla, CA, USA).
P-values less than 0.05 were considered statistically signif-
icant. The mean values±mean standard error (SEM) are
presented in the figures and text. All graphs were generated
by using the GraphPad® Prism 5.0 (GraphPad Software, Inc.,
La Jolla, CA, USA).
Results
Characterization of hESC-NPCs and hfNPCs
hESC-NPCs were successfully developed from hESCs by
double blocking the SMAD signaling pathway as described
by Chambers et al. (2009) in suspension cultures. Immuno-
cytochemistry for pluripotency and neural markers revealed
that after neural induction hESC-NPCs, as well as hfNPCs
derived from first trimester spinal cord, were negative for
the pluripotency marker nanog and positive for neural
markers Pax6, nestin, β-tubulin III and glial fibrillary acidic
protein (GFAP) (Fig. 1A). hESC-NPCs and hfNPCs were
capable of differentiating into neurons and glial cells (data
not shown). In addition, hESC-NPCs were negative for the
endodermal marker α-fetoprotein, and presented only a
small number of cells immunoreactive for the mesodermal
marker Brachyury (Supplementary Fig. 1A).
Flow cytometry revealed that in cultures of hESC-NPCs and
hfNPCs, cells expressing the pluripotency markers Stage-
specific embryonic antigen 4 (SSEA-4, 0–10%), Tra-1-60 (0–5%)
or Tra-1-81 (0–9%) were either few or absent in sharp contrast
to the original hESCs (Fig. 1B, Pb0.05). The proportion of cell
expressing CD24, a marker associated with pluripotent hESCs
(Skottman et al., 2005), decreased significantly from 80% in
hESCs to less than 5% in hESC-NPCs and hfNPCs (Fig. 1B,
Pb0.05). After neural induction some populations of hESC-NPCs
contained a few cells positive for the mesodermal marker
Brachyury (0–7%) or the endodermal marker CD31 (0–3%)
(Supplementary Fig. 1B). As expected, the proportion of
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Figure 1 Characterization of hESC-NPCs and hfNPCs. (A) Immunocytochemical characterization of hNPCs. Representative
microphotographs of neurospheres labeled with pluripotent marker Nanog (a, b), neural markers Nestin (c-i, d-i), Pax6 (c-ii, d-ii),
β-tubulin III (g, h) and GFAP (i, j) and proliferation marker Ki67 (e, f) by hESC-NPCs and hfNPCs. Nuclei are labeled blue (Hoechst).
Scale bar=50μm. (B) Flow cytometric analysis of pluripotent and neural markers in hESC-NPCs and hfNPCs. Expression of SSEA-4,
Tra-1-60, Tra-1-81, CD15, CD24, CD29, CD44, CD56, CD184, PSA-NCAM, A2B5 and Ki67 by hESCs (n=3), hESC-NPCs (n=3) and hfNPCs
(n=6) were compared by flow cytometry. Mean values±SEM. *Pb0.05. §Pb0.05, compared to hESC-NPCs and hfNPCs.
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CD184, PSA-NCAM and A2B5) were significantly larger than in
the original pluripotent hESCs (Fig. 1B, Pb0.05).
hfNPCs presented a higher percentage of the glial
progenitor marker A2B5 and neural cell growth and migration
modulator CD184 positive cells (Fig. 1B, Pb0.05) compared to
hESC-NPCs. Both hESC-NPCs and hfNPCs expressed similarly
moderate amounts of neuronal progenitor marker PSA-NCAM
while high percentage of CD29 (modulating NPC proliferation,
survival, migration and differentiation (Campos, 2005)), CD44
(expressed on glial progenitors and astrocytes (Liu et al.,
2004)) and the neural cell adhesion molecule CD56 (Fig. 1B).
The proliferative capacity of hESC-NPCs and hfNPCs
was evaluated by immunocytochemistry of either intact
neurospheres or cell suspensions by flow cytometry with the
proliferative marker Ki67. Both neural cell populationspresented moderate to high numbers of proliferating cells
(Figs. 1A-e, f & 1B).hESC-NPCs and hfNPCs showed similar expression of
immune-related proteins
Under normal culturing conditions, both hESC-NPCs and
hfNPCs expressed high percentage of HLA-I (N85%,
Fig. 2A). hESC-NPCs expressed HLA-I with a MFIb50 while
the MFI was N300 on hfNPCs. In contrast, less than 10% of
hESC-NPCs and hfNPCs expressed HLA-II (Fig. 2B), with low
MFI (b10) on both. To further evaluate expression of
proteins involved in antigen processing and presentation,
the expression of co-stimulatory molecules (CD40, CD80
and CD86) and the two adhesion molecules CD54 (binding/
330 J. Liu et al.ligation to lymphocyte function-associated antigen 1 and
stabilizing cell–cell interactions) and CD58 (binding/
ligation to CD2 on T cells and strengthening the adhesion
to T cells) were analyzed by flow cytometry. Both hNPC
types expressed low percentage of CD54 (≤25%) but high
percentage of CD58 (≥80%) (Figs. 2C & D). Less than 5% of
hESC-NPCs and hfNPCs expressed CD80 and CD86 molecules
(Figs. 2F & G). In contrast, the proportion of CD40 positive
hESC-NPCs was significantly lower compared to that of
hfNPCs (3% vs 8% respectively) (Fig. 2E, Pb0.05). The MFI of
co-stimulatory and adhesion molecules was low (MFIb30) and
showed no significant differences between hESC-NPCs and
hfNPCs. Finally, the percentage of HLA-I+CD40+ CD80+CD86+
hfNPCs was 3%–5%, but undetectable on hESC-NPCs. The
co-expression of HLA-II and all co-stimulatory molecules was
undetectable on both hESC-NPCs and hfNPCs.
To evaluate whether inflammatory cytokine exposure of
relevance for traumatic CNS lesions and an invasive surgical
cell implantation procedure could affect the immunocom-
petence of hNPCs, cells were treated with IFN-γ and/or
TNF-α for three days prior to analysis. Flow cytometryHLA-I
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Figure 2 hESC-NPCs and hfNPCs showed relatively similar exp
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(C) CD54, (D) CD58, (E) CD40, (F) CD80, and (G) CD86. Mean values±data demonstrated that HLA-I and II, CD58 as well as
co-stimulatory molecule expression on hESC-NPCs and
hfNPCs, were unaffected by IFN-γ and/or TNF-α treatment
(Figs. 2A–B and D–G). In contrast, CD54 expression on
hfNPCs was significantly up-regulated by TNF-α, but not by
IFN-γ (Fig. 2C, Pb0.05).
Cytokine secretion by hESC-NPCs and hfNPCs
Secreted cytokines by hNPCs may influence the host human
immune response following allogeneic neural cell therapy.
We analyzed whether and in what amount some cytokines of
interest were secreted by hESC-NPCs and hfNPCs. Fetal CNS
derived hfNPCs secreted significantly more TGF-β1 and β2
compared to hESC-NPCs under normal culture conditions
without stimulation (Fig. 3A, Pb0.05). Both hESC-NPCs and
hfNPCs secreted low levels of IL-10 (b50 pg/106 cells,
Fig. 3A). The release levels of TGF-β1, TGF-β2 or IL-10 by
hESC-NPCs were significantly increased under stimulation
with IFN-γ and TNF-α (Figs. 3B–D, Pb0.05). In contrast,
stimulation with IFN-γ and/or TNF-α did not significantlyA-II
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and the secretion of TGF-β2 by hfNPCs decreased in the
presence of IFN-γ or the combination of IFN-γ and TNF-α
(Fig. 3C, Pb0.05). To rule out background signals, we
analyzed the growth medium alone and found undetectable
levels of these studied cytokines.
Furthermore, to investigate whether TGF-β could exert
effects on PBMC proliferation, different concentrations of
hTGF-β1 or 2 (in a range comparable to that secreted by
cultured hNPCs) were added to PBMCs stimulated with PHA.B
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332 J. Liu et al.The cell death, differentiation and expression of HLA and
co-stimulatory molecules by hNPCs after 6 days in RPMI
medium did not significantly differ from those in their naïve
NS medium (Supplementary Fig. 2).
As shown in Fig. 4A, there was no increase in PBMC
proliferation after addition of hESC-NPCs at a ratio 1:10 or
hfNPCs at a ratio of 1:1 or 1:10. In contrast, a significant
increase in PBMC proliferation was seen when hESC-NPCs, at a
ratio 1:1, were present in the culture compared to the
negative control (Pb0.05) or hfNPCs (Pb0.05). To further
demonstrate that PBMC response can be modulated by
TGF-β1, proliferation of PBMCs in response to hNPCs was
studied in the presence of anti-hTGF-β1 neutralizing anti-
bodies (Fig. 4A). When hfNPCs and PBMCs were co-cultured
in the presence of anti-hTGF-β1 neutralizing antibodies,
PBMC proliferation was significantly enhanced compared
to without neutralizing antibodies and negative control
(Pb0.05, Fig. 4A). However, no significant neutralization of
hTGF-β1 effect was observed in co-cultures of hESC-NPCs and
PBMCs.
To further investigate the role of alloantigens in immune
recognition and induction of PBMC proliferation, hESC-NPCshE
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Co-cultures of stimulated hESC-NPCs or hfNPCs at a ratio of
1:10 with human PBMCs did not induce PBMC proliferation.
The higher ratio of hfNPCs (1:1) showed similar results.
However, as shown in Fig. 4B, addition of hESC-NPCs at
the ratio 1:1 significantly induced PBMC proliferation, with
comparable results for IFN-γ and/or TNF-α stimulated cells
(Pb0.05).
To study which PBMC subpopulation was mostly affected by
hNPCs, purified human CD4 and CD8 T cells were co-cultured
with irradiated hESC-NPCs or hfNPCs. CD8 T cell proliferation
was not significantly influenced by hESC-NPCs or hfNPCs (data
not shown). However, the proliferation of CD4 T cells
was significantly stimulated in the presence of hESC-NPCs
(Pb0.05, Fig. 4C), but not hfNPCs.
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333Immunogenicity and immunomodulatory effects of human neural stem/progenitor cellsco-cultured with human PBMCs either allowing cell–cell
contact, or in a Transwell system with the hNPCs and PBMCs
in separate chambers eliminating cell–cell contact but not
diffusion of soluble molecules. To evaluate the possible
influence of cell death, we also analyzed CD4+ T cells with
the necrosis marker 7-AAD. A low percentage, less than 1%
7-AAD+ CD4 T cells, was observed in either hNPC co-cultures.
After 3 days, the percentage of CD4+ T cell and CD4+CD25+
T cells among CD4+ T cells significantly increased in the cell–
cell contact system in the presence of hESC-NPCs (Pb0.05,
Figs. 5A & B); while the proportion of CD4+CD25+FOXP3+
T cells among CD4+ T cells did not change, in cell–cell contact
or Transwell co-culture of hESC-NPCs or hfNPCs with human
PBMCs (Fig. 5C). After 6 days of co-culture, the proportion of
CD4+ T cells and CD4+CD25+FOXP3+ T cells among CD4+ T cells
was significantly increased in the cell–cell contact system in
the presence of hESC-NPCs or hfNPCs (Figs. 5A & C, Pb0.05);
while the percentage of CD4+CD25+ T cells among CD4+ T cells
was further increased in the cell–cell contact co-cultures in
the presence of hESC-NPCs (Pb0.05, Fig. 5B). The proportion
of CD8+ T cells was not significantly affected in cell–cell
contact or Transwell systems (data not shown).PB
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Figure 5 hESC-NPCs and hfNPCs increased CD4+CD25+FOXP3+ T
co-cultured with PBMCs either with cell–cell contact or in transwell
CD4+ T cells, CD4+CD25+ T cells and CD4+CD25+FOXP3+ T cells was
independent experiments). *Pb0.05.hESC-NPC and hfNPC effects on cytokine release in
PBMC co-cultures
To further study whether hESC-NPCs and hfNPCs influence
cytokine production in a PBMC co-culture system, the
presence and levels of soluble cytokines in the culture
medium were analyzed by ELISA and flow cytometry.
In the co-cultures with cell–cell contact including
hESC-NPCs, the release level of TGF-β1 showed no signifi-
cant changes (Fig. 6A). In contrast, in the presence of
hfNPCs, the concentration of TGF-β1 was significantly higher
compared to mono-cultures after 6 days (Fig. 6A, Pb0.05).
The concentration of TGF-β2 was not significantly affected
in the cell–cell contact cultures (Fig. 6B), while in the
transwell cultures, the level of TGF-β2 significantly decreased
after 6 days in the presence of either hESC-NPCs or hfNPCs
(Fig. 6B, Pb0.05). The release of IL-10 in co-cultures did not
significantly differ from mono-cultures (data not shown). The
concentration of IL-6 was not significantly affected in the
cell–cell contact system in the presence of hESC-NPCs or
hfNPCs compared to PBMC mono-culture. In the transwell
culture, the concentration of IL-6 was significantly higher thanPB
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Figure 6 hESC-NPCs and hfNPCs affected the cytokine production in co-cultures with PBMCs. hESC-NPCs (n=3) and hfNPCs (n=5) were
co-cultured with PBMCs in RPMI medium either in cell–cell contact or in transwell culture system. After 6 days in co-culture, the media
was collected and the levels of (A) TGF-β1, (B) TGF-β2, (C) IL-6 and (D) TNF-αwere measured by ELISA. (E) Flow cytometry analyzing the
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all other groups.
334 J. Liu et al.that in cell–cell contact co-culture in the presence of hfNPCs
after 6 days (Fig. 6C, Pb0.05). The release of TNF-α was not
significantly affected in the presence of hESC-NPC (Fig. 6D). In
contrast, the reduction in TNF-α levels appeared robust with
significant reductions in both cell–cell contact and transwell
hfNPC co-cultures compared to PBMC mono-culture after
6 days (Fig. 6D, Pb0.05).
In addition, the proportion of cells in the respective
population expressing TGF-β1 was evaluated by flow
cytometry. In the cell–cell contact system, the proportion
of TGF-β1+ PBMCs was significantly higher in the presence of
either hNPCs compared to the control PBMCs (Pb0.05,
Fig. 6E). Furthermore, a larger proportion of hfNPCs in
cell–cell contact system expressed TGF-β1 compared to
hESC-NPCs in cell–cell contact co-cultures and hfNPCs in
transwell system (Pb0.05, Fig. 6E).
hESC-NPCs and hfNPCs reduce a human alloresponse
among allogeneic PBMCs
To evaluate how hESC-NPCs and hfNPCs may influence a
third party alloresponse between human PBMC populations,PBMCs were stimulated with a pool of PBMCs from five
different donors with or without hNPCs present at different
cell ratios. Neither hESC-NPCs nor hfNPCs further triggered
the human allogeneic responses. On the contrary, significant
reductions in the proliferative response were observed when
hESC-NPCs or hfNPCs at the ratio of 1:1 were present
compared to the positive control (Fig. 7, Pb0.05).Discussion
In the present study, we report that two potential neural
donor cell populations, hESC-NPCs and hfNPCs cultured
under equivalent conditions displayed similarities but also
significant differences in their immunocompetence and
interaction with allogeneic PBMCs.
Both hESC-NPCs and hfNPCs have a high percentage of
HLA-I+ cells, while the proportion of cells expressing HLA-II
and co-stimulatory molecules CD40, CD80 and CD86 was not
existing. Cells expressing CD40 were more common among
hfNPCs than hESC-NPCs. Expression of CD40 but not CD80
and 86 molecules on carcinoma cells has been reported not
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Figure 7 hESC-NPCs and hfNPCs reduce a human alloresponse among allogeneic PBMCs. Irradiated hESC-NPCs (n=3) and hfNPCs (n=4)
were co-cultured with PBMCs in the presence of an irradiated pool of five PBMC populations at the ratio of 1:1 or 1:10. As positive (pos)
control were PBMCs co-cultured with non-compatible allogeneic pool PBMCs (allo) from five donors. As negative control, PBMCs were
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other groups.
335Immunogenicity and immunomodulatory effects of human neural stem/progenitor cellsto trigger mixed lymphocyte reactions (Vonderheide et al.,
2001), which our present findings corroborate. The expres-
sion pattern of these markers indicates that the antigen
presentation to induce naïve T cells in theory can occur but
is limited due to the lack expression of HLA-II, adhesion and
co-stimulatory molecules on the same cells. In this study,
none of these molecules was further affected by cytokine
stimulation in any of the hNPCs, further supporting the
hypothesis of a limited risk of triggering an immune response
by hESC-NPCs or hfNPCs, even in an ongoing inflammatory
environment.
Varying results have been reported on hESC-derived neural
derivates and their potential to trigger proliferation and
an alloresponse by PBMCs. Okamura et al. reported that
oligodendrocyte progenitor cells derived from hESCs, similarly
as undifferentiated hESCs, failed to induce PBMC proliferation
in vitro (Okamura et al., 2007). In contrast, hESC-NPCs elicited
a significant proliferative response, which was further
increased upon preincubation with IFN-γ (Preynat-Seauve
et al., 2009). In the present study, we showed that hESC-NPCs
trigger PBMC proliferation in a dose-dependent manner,
and the response was not affected by IFN-γ and/or TNF-α. In
contrast, hfNPCs tested under equivalent conditions did
not elicit an allogeneic PBMC proliferation, which is consistent
with our previous findings on hfNPCs and their differen-
tiated derivates (Odeberg et al., 2005; Akesson et al., 2009).
Noteworthy is the report by, Laguna Goya et al. (2011), that
hfNPCs triggered a delayed proliferative response of alloge-
neic T cells after 14 days in vitro.
Despite the fact that hESC-NPCs can trigger PBMC prolifer-
ation, we here report that neither hESC-NPCs nor hfNPCs
further enhance a PBMC alloresponse triggered by third party
allogeneic PBMCs, but rather hinder the proliferative response.
This effect occurred in a dose-dependent way and was neither
increased nor decreased by the addition of inflammatory
cytokines in the cultures. Similar findings were also observed
with pluripotent hESCs by others, showing a dose-dependent
inhibitory effect by hESCs when human PBMCs were challenged
in the presence of fixed dead hESCs (Li et al., 2004).
Mesenchymal stem cells are known to have strong immune
suppressive properties on all cells of the immune system, and
can even counteract graft versus host disease in clinical
hematopoietic stem cell therapies (Le Blanc et al., 2008).
However, their immunosuppressive function requires activa-
tion by a pro-inflammatory environment to suppress immune
cells (Engela et al., 2012). Here, we show that when hESC-NPCsare in cell–cell contact with one naïve PBMC population, they
induce an alloreactive response. In contrast, when hESC-NPCs
or hfNPCs were co-cultured with a pool of incompatible
allogeneic PBMC, immunosuppressive processes were activated
to reduce the PBMC alloresponse.
hESC-NPCs and hfNPCs induced different PBMC prolifera-
tive responses, despite relatively similar expression levels of
HLA, co-stimulatory and adhesion molecules. Multiple other
factors that are produced by NPCs and may contribute to the
regulation of the immune response such as inducible nitric
oxide synthase, prostaglandin E2 and Heme Oxygenases (Wang
et al., 2009; Bonnamain et al., 2012). In the present study,
compared to hESC-NPCs, unstimulated hfNPCs secreted higher
levels of TGF-β1, a factor involved in the maintenance of
immune tolerance and T-cell homeostasis (Bommireddy and
Doetschman, 2007) and also previously reported to balance
the immunogenicity of human forebrain derived NPCs
(Ubiali et al., 2007). In addition, the higher release of
TGF-β2 by hfNPCs may polarize naïve T cells toward a
regulatory function, mediating suppression transplantation
and antagonizing adaptive immune responses (Robertson
et al., 2007). On the other hand, the release of TGF-β1,
TGF-β2 and IL-10 by hESC-NPCs was significantly increased
under inflammatory conditions. Ubiali et al. (2007) reported a
marked reduction of TGF-β1 release by hNPCs after 3 days of
inflammatory stimulation, which differs from what we found
here. Our findings indicate that the production of immuno-
modulatory factors and thereby the immunomodulatory
potential of hESC-NPCs is promoted when they encounter
pro-inflammatory cytokines such as those expressed in
neurodegenerative diseases and CNS trauma.
A recent study showed that syngeneic mouse NPCs
transplanted in a model of focal SCI were able to increase the
proportion of Tregs (Cusimano et al., 2012), which are known to
promote antigen-specific peripheral tolerance by suppressing
the activation and expansion of reactive effector cells. Herewe
observed that both hESC-NPCs and hfNPCs up-regulated Tregs,
defined as the proportion of CD4+CD25+FOXP3+ T cells among
CD4+ T cells, after 6 days of co-culture when in direct cell–cell
contact. Next, we introduced a transwell system to elucidate
whether the up-regulation was cell–cell contact dependent or
not. The proportion of CD4+CD25+FOXP3+ T cells was not
significantly up-regulated in the transwell system. These data
suggested that cell–cell contact between hNPCs and PBMCs
is an important mechanism to up-regulate CD4+CD25+FOXP3+
T cells. In coherence, Han et al. (2011) showed that the
336 J. Liu et al.immunosuppressive effects of mouse ESCs and MSCs were
mainly mediated by cell–cell contact.
The production of immunosuppressive cytokines such as
TGF-β1 is one of the major pathways by which Tregs exert
their suppressive function. Li et al. (2007) reported that
T-cell-specific deletion of TGF-β1 causes T-cell activation
and defective Treg function. Bommireddy et al. (2009)
showed that FOXP3+ Tregs in TGF-β1−/− mice were unable
to prevent the activation of CD4+CD25+ T cells, indicating the
expression of FOXP3 alone in Tregs is not sufficient for their
function, suggesting that TGF-β1 is required for the suppres-
sive function of Tregs. In the present study, we showed that
the release of TGF-β1 was coherent with the up-regulation of
CD4+CD25+FOXP3+ T cells in the presence of hfNPCs when
allowing direct contact with PBMCs, but not hESC-NPCs.
Furthermore, in co-cultures with PBMCs, we showed that
hESC-NPCs under the present conditions triggered PBMC
proliferation, while hfNPCs did not. We further showed that
PBMC proliferative response may be reduced by the exoge-
nous addition of hTGF-β and that hTGF-β1 antibodies may at
least partly interfere and result in a higher proliferative
response in co-cultures of PBMC and hNPCs. Taken together,
these events may suggest that TGF-β1 released at high
enough levels by hNPCs may support the induced FOXP3+ Treg
population to exert their suppressive effects. Interestingly,
after 6 days, we observed that TGF-β2 significantly de-
creased in the transwell system, which may be due to the
high level of IL-6 and TNF-α present to inhibit TGF-β2
secretion as previously reported in experimental autoim-
mune encephalomyelitis (Siglienti et al., 2007).
In summary, hESC-NPCs and hfNPCs cultured under equiv-
alent conditions presented differences in immunogenicity and
immunomodulatory effects in vitro, despite relatively similar
expression of transplantation antigens, co-stimulatory and
adhesionmolecules. Awareness of available donor neural cells'
varying characteristics and potentials offers the opportunity
to match donor–host with higher accuracy and to design
necessary immunosuppressive treatments in clinical cell
therapy in neurodegenerative disorders and CNS trauma.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.01.001.
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